Johnson & Johnson (NYSE:JNJ) Declares Quarterly Dividend of $1.24

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Tuesday, October 15th,RTT News reports. Investors of record on Tuesday, November 26th will be given a dividend of 1.24 per share on Tuesday, December 10th. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date is Tuesday, November 26th.

Johnson & Johnson has increased its dividend by an average of 5.7% per year over the last three years and has raised its dividend annually for the last 63 consecutive years. Johnson & Johnson has a dividend payout ratio of 46.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $10.54 per share next year, which means the company should continue to be able to cover its $4.96 annual dividend with an expected future payout ratio of 47.1%.

Johnson & Johnson Trading Down 0.2 %

JNJ stock opened at $155.17 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The stock has a market cap of $373.59 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.76 and a beta of 0.53. The business’s 50-day moving average is $160.21 and its 200 day moving average is $156.26.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Citigroup lifted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Guggenheim boosted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.